Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARPi, BRCA, and gaps: controversies and future research

14 Jul 2024

Abstract excerpt

In recent years, various poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) have been approved for the treatment of several cancers to target the vulnerability of homologous recombination (HR) deficiency (e.g., due to BRCA1/2 dysfunction). In this review we analyze the ongoing debates and recent breakthroughs in the use of PARPis for BRCA1/2-deficient cancers, juxtaposing the 'double-strand break (DSB)' and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39004561
DOI: 10.1016/j.trecan.2024.06.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARPi, BRCA, and gaps: controversies and future researchPMID 39004561Read ↗

BRCAness, DNA gaps, and gain and loss of PARP inhibitor–induced synthetic lethalitySemantic proximity Read ↗

‘Where is my gap’: mechanisms underpinning PARP inhibitor sensitivity in cancerSemantic proximity Read ↗

Recent advancements in PARP inhibitors-based targeted cancer therapySemantic proximity Read ↗

The potential of PARP inhibitors in targeted cancer therapy and immunotherapySemantic proximity Read ↗

Synthetic Lethality in Cancer: Mechanistic and Therapeutic Insights into PARP Inhibitors, BRCA Mutations, and Homologous Recombination Deficiency (HRD)Semantic proximity Read ↗

PARP1 roles in DNA repair and DNA replication: The basi(c)s of PARP inhibitor efficacy and resistanceSemantic proximity Read ↗

Poly (ADP-ribose) polymerase inhibitors in cancer therapySemantic proximity Read ↗

DNA double-strand break repair pathway choice - from basic biology to clinical exploitationSemantic proximity Read ↗

Mechanisms of PARP1 inhibitor resistance and their implications for cancer treatmentSemantic proximity Read ↗

Harnessing DNA Double-Strand Break Repair for Cancer TreatmentSemantic proximity Read ↗

Advances and perspectives of PARP inhibitorsSemantic proximity Read ↗

A new wave of innovations within the DNA damage responseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.